Flow Mediated Dilation in Association With Hyperuricemia
NCT05342285 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2022-07-20
Summary
Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation.
evaluate the role of uric acid as independent marker of cardiovascular risk in systemic lupus patient
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Flow mediated dilation
flow mediated dilation in brachial artery
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Rafaat fathy · [email protected]
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-07-30
- Primary Completion
- 2022-12-27
- Completion
- 2023-12-27
Countries
- Egypt
Study Locations
More Related Trials
-
Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.
NCT06294483 ·Status: ENROLLING_BY_INVITATION
-
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
NCT06631404 ·Status: RECRUITING
-
Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant
NCT05416190 ·Status: COMPLETED ·Phase: NA
-
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
NCT05479071 ·Status: UNKNOWN
-
Unmet Needs of Axial Spondyloarthrits in Egyptian Patients
NCT05517031 ·Status: UNKNOWN
-
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
NCT03122431 ·Status: COMPLETED ·Phase: PHASE4
-
Premature Atherosclerosis in Systemic Lupus Erythematosus
NCT04037293 ·Status: UNKNOWN
-
Haematological Indices in Systemic Lupus Erythematosus
NCT04110184 ·Status: UNKNOWN
-
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
NCT00005436 ·Status: COMPLETED
-
Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients
NCT04024306 ·Status: UNKNOWN
-
Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus
NCT06151990 ·Status: RECRUITING
-
Urinary Congophilia As an Indicator of Activity of Lupus Nephritis
NCT06654024 ·Status: NOT_YET_RECRUITING
-
Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus
NCT04970199 ·Status: COMPLETED ·Phase: NA
-
Cardiology Prevention in Systemic Lupus Erythematosus (SLE)
NCT00610805 ·Status: WITHDRAWN ·Phase: NA
-
Systemic Lupus Erythematous and Heart Conduction Disorders
NCT02162992 ·Status: COMPLETED
-
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
NCT04018222 ·Status: UNKNOWN
-
Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
NCT04580108 ·Status: COMPLETED
-
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
NCT00054938 ·Status: COMPLETED ·Phase: PHASE2
-
Neuromuscular Ultrasonography Utility for Detection of Peripheral Neuropathy in Systemic Lupus Erythematosus
NCT04527172 ·Status: COMPLETED
-
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
NCT07130448 ·Status: NOT_YET_RECRUITING
-
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT04530461 ·Status: UNKNOWN
-
Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit
NCT05418855 ·Status: UNKNOWN
-
Insulin Resistance and Atherosclerosis in Women With Lupus
NCT00544102 ·Status: COMPLETED
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
NCT03958851 ·Status: UNKNOWN